Industry

Poster presentations by Dr. Philip Lavin, a biostatistician for 80 FDA approvals/clearances, and Dr. József Tímár, Professor and Director of the Central Pathology Laboratory at Semmelweis University View the posters here: LINK VIENNA, Va.–(BUSINESS WIRE)–$CVM #ESMO22–CEL-SCI Corporation (NYSE American: CVM) today announced two poster presentations were delivered at the European Society for Medical Oncology (EMSO) … [Read more…]

NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech’s 2022 “Fierce 15,” designating it as one of the most promising early-stage biotechnology companies in the industry. “It is an honor and tremendous validation of our team and progress … [Read more…]

Hani Zeini is a 20+ year executive in the breast aesthetics industry, including as CEO and Founder of Sientra SANTA BARBARA, Calif.–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has retained Hani Zeini to an exclusive, … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#Fierce15—Strand Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry. Founded by leaders in mRNA-based synthetic biology at MIT, Strand is creating the first platform for programmable, long-acting mRNA therapeutics. The … [Read more…]

Dr. Schott will oversee the advancement of Nutcracker Therapeutics’ oncology pipeline, helping to expand the company’s novel RNA therapeutics platform The announcement follows several recent C-suite hires, adding significant pharmaceutical industry and drug development experience to Nutcracker Therapeutics’ executive team EMERYVILLE, Calif.–(BUSINESS WIRE)–Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through … [Read more…]

Bolstering Industry Capabilities for Gongos, the North American Arm of InSites Consulting ROYAL OAK, Mich.–(BUSINESS WIRE)–Gongos, the North American arm of InSites Consulting, has announced that Meaghan Hafner has been appointed to Vice President, Health Care for the company. With this appointment, Hafner will bring enhanced and strengthened capabilities in the health care industry for … [Read more…]

Dr. Papp: “The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options especially given the chronic nature of psoriasis which can necessitate long-term treatment.” Piclidenoson has a safety profile similar to placebo and is better tolerated than Otezla® Efficacy of Piclidenoson is similar … [Read more…]

TORONTO–(BUSINESS WIRE)–Mednow Inc. (“Mednow” or the “Company”) (TSXV:MNOW) (OTCQX:MDNWF), Canada’s on-demand virtual pharmacy, will participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022. The presentation will be available on demand at the H.C. Wainwright Conference Platform for 30 days. Mednow will be introducing its story to new potential investors and … [Read more…]

Confirmed single agent overall response rate of 43% and median duration of response of 17.8 months in MAPK-inhibitor naïve, V600+ population; 71% experienced clinical benefit of at least 24 weeks Responses observed in Primary CNS Tumors including both high grade and low grade gliomas FORE8394 is well-tolerated, with any adverse events being transient and manageable … [Read more…]

– Financing supports ongoing Phase 2b clinical trials of NDI-034858 (allosteric TYK2 inhibitor) and initiation of Phase 3; ongoing Phase 1/2 clinical trials of NDI-101150 (HPK1 inhibitor); and advancement of multiple preclinical programs – – Bain Capital Life Sciences and SV Health Investors participating as new investors – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company … [Read more…]